-
01:00:01 AM

VTGN Stock News

01/24/23 8:30 AM
Nasdaq : VTGN
clinical trial
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder
Vistagen a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders, today announced the first cohort of healthy volunteers has been dosed in its U.S. Phase 1 clinical trial of PH10, the Company’ s investigational pherine nasal...
RHEA-AI
neutral
01/10/23 8:30 AM
Nasdaq : VTGN
clinical trial
Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety
The exploratory Phase 2 clinical trial is a U.S. multi-center, randomized, double-blind, placebo-controlled study intended to evaluate efficacy, safety and tolerability of PH94B administered four times per day over four weeks for the treatment adjustment disorder with anxiety symptoms in adults. Michael Liebowitz, a former Columbia University...
RHEA-AI
neutral
12/30/22 8:30 AM
Nasdaq : VTGN
Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder
Vistagen, a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system disorders, today announced that the Company has taken important strategic steps to secure additional patent protection for its lead product candidate, PH94B, through...
RHEA-AI
neutral
12/06/22 8:30 AM
Nasdaq : VTGN
Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder
Vistagen a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders, today announced the U.S. Food and Drug Administration has granted Fast Track designation for the development of PH10, one of the Company’ s investigational...
RHEA-AI
very positive
11/30/22 8:30 AM
Nasdaq : VTGN
Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder
Vistagen, a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders, today announced receipt of a“ Study May Proceed” letter from the U.S. Food and Drug Administration. The letter greenlights a U.S. Phase 1 clinical trial under...
RHEA-AI
neutral
11/17/22 8:30 AM
Nasdaq : VTGN
Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
Vistagen a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders, today announced the publication of positive results from a preclinical study of the effects of AV-101, its oral NMDA receptor glycine site antagonist, in a...
RHEA-AI
neutral
11/04/22 8:30 AM
Nasdaq : VTGN
conferencesearnings
Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
Vistagen, a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders, today announced it will host a conference call and webcast on Thursday, November 10, 2022, at 2:00 p.m. Pacific Time to report financial results for its fiscal...
RHEA-AI
neutral